“…Neuroimaging meta‐analysis including CBMA has been widely used in various neuropsychiatric disorders such as depression (Kaiser, Andrews‐Hanna, Wager, & Pizzagalli, ; Lai, ; Muller et al, ; Sacher et al, ), bipolar disorder (Wang et al, ; Wegbreit et al, ), schizophrenia (Brandl et al, ; Jardri, Pouchet, Pins, & Thomas, ; Xiao, Zhang, Lui, Yao, & Gong, ), Alzheimer's disease (Ferreira, Diniz, Forlenza, Busatto, & Zanetti, ; Schroeter, Stein, Maslowski, & Neumann, ; Wang et al, ), Parkinson's disease (Herz, Eickhoff, Lokkegaard, & Siebner, ; Tahmasian et al, ; Wang, Zhang, Zang, & Wu, ), post‐traumatic stress disorder(Kuhn & Gallinat, ; Ramage et al, ; Wang et al, ), sleep disorders (Javaheipour et al, ; Shi et al, ; Tahmasian et al, ; Tahmasian et al, ), as well as neurodevelopmental disorders such as autism (Dickstein et al, ; Nickl‐Jockschat et al, ) and attention‐deficit/hyperactivity disorder (ADHD) (Cortese et al, ; Cortese et al, ; Hart, Radua, Mataix‐Cols, & Rubia, ; Hart, Radua, Nakao, Mataix‐Cols, & Rubia, ; Samea et al, ).…”